Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non‐alcoholic steatohepatitis
- 4 May 2020
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 35 (12) , 2140-2150
Abstract
Background and Aim: Non‐alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation, and hepatocellular injury with varying degrees of fibrosis. There are currently no established treatment approaches for NASH other than lifestyle interventions. Periostin, a matricellular protein required for tissue remodeling and fibrosis, plays an important role in hepatic steatosis and fibrosis and could be a potential target for NASH treatment. Advances in molecular biology and biochemical engineering have led to the development of antisense oligonucleotides (ASOs) that can inhibit target genes with no significant toxic effects. Herein, we investigated the therapeutic effects of periostin‐targeting ASO (PNASO) in NASH.Methods: C57BL/6J mice were fed a choline‐deficient, l‐amino acid‐defined, high‐fat diet (CDAHFD) to induce NASH with or without intraperitoneal injection of mouse PNASO. To explore the role of periostin in hepatocellular steatosis, Hc3716 cells, an immortalized human hepatocyte line, were treated with recombinant periostin in vitro.Results: The induced periostin expression in the liver of CDAHFD‐fed mice was significantly suppressed by PNASO. The deletion of hepatic periostin by PNASO significantly ameliorated hepatic steatosis while restoring the expression levels of peroxisome proliferator‐activated receptor‐alpha (PPAR‐α) and its target genes. PNASO also inhibited hepatic fibrosis, reflected by the reduction of alpha‐smooth muscle actin, collagen type I, and other fibrotic markers. In vitro experiments demonstrated that treatment with recombinant periostin increased cellular lipid accumulation in Hc3716 cells accompanied with the downregulation of PPAR‐α.Conclusions: Periostin‐targeting ASO is a potential therapeutic approach for the efficient treatment of hepatic steatosis and fibrosis in NASH.Keywords
Funding Information
- Fellowships for Young International Scientists
This publication has 41 references indexed in Scilit:
- The chemical evolution of oligonucleotide therapies of clinical utilityNature Biotechnology, 2017
- Therapies in non‐alcoholic steatohepatitis (NASH)Liver International, 2017
- Circulating periostin in patients with nonalcoholic fatty liver diseaseEndocrine, 2016
- Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via αv integrin interactionJournal of Gastroenterology, 2016
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and OutcomesClinical Gastroenterology and Hepatology, 2015
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2015
- Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARαJournal of Clinical Investigation, 2014
- The role of periostin in tissue remodeling across health and diseaseCellular and Molecular Life Sciences, 2013
- Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment ApproachesDrugs, 2013
- Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cellCellular and Molecular Life Sciences, 2011